Johannes Hofland
Overview
Explore the profile of Johannes Hofland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
1045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atila C, Lustenberger S, Chifu I, Ferrante E, Erlic Z, Drummond J, et al.
Pituitary
. 2025 Jan;
28(1):18.
PMID: 39863827
Background: Arginine infusion stimulates copeptin secretion, a surrogate marker of arginine vasopressin (AVP), thereby serving as a diagnostic test in the differential diagnosis of suspected AVP deficiency (AVP-D). Yet, the...
2.
Ling S, de Lussanet de la Sabloniere Q, Ananta M, de Blois E, Koolen S, Drexhage R, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39825041
Purpose: To report real-world clinical experience with [Lu]Lu-PSMA-I&T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital. Methods: Patients with...
3.
Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose C, Pavel M, et al.
J Neuroendocrinol
. 2024 Dec;
37(2):e13479.
PMID: 39653582
Assessing the response to systemic therapy in neuroendocrine tumors (NET) is challenging since morphological imaging response is often delayed and not necessarily reflective of clinical benefit. Peptide receptor radionuclide therapy...
4.
Mulders M, Van Koetsveld P, Feelders R, Hofland L, de Herder W, Kraaij R, et al.
Endocr Relat Cancer
. 2024 Dec;
32(2.
PMID: 39635985
Midgut neuroendocrine tumors (NET) derive from enterochromaffin cells, which have a close interrelationship with intestinal microbiota. Recently, we have utilized 16S rRNA sequencing to uncover that midgut NET patients have...
5.
Kuiper J, Zoetelief E, Brabander T, de Herder W, Hofland J
J Neuroendocrinol
. 2024 Nov;
:e13469.
PMID: 39563515
Peptide receptor radionuclide therapy (PRRT) using [Lu-DOTA,Tyr]octreotate (Lu-DOTATATE) represents an established treatment modality for somatostatin receptor-positive, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NET) of grade 1 or 2....
6.
Mulders M, Verschuur A, de Lussanet de la Sabloniere Q, Roes E, Geisenberger C, Brosens L, et al.
J Pathol Clin Res
. 2024 Nov;
10(6):e70000.
PMID: 39513463
Currently, the available literature provides insufficient support to differentiate between primary ovarian neuroendocrine tumors (PON) and neuroendocrine ovarian metastases (NOM) in patients. For this reason, patients with a well-differentiated ovarian...
7.
Boss M, Eriksson O, Mikkola K, Eek A, Brom M, Buitinga M, et al.
J Nucl Med
. 2024 Oct;
65(12):1959-1964.
PMID: 39419553
Precise anatomic localization of insulinomas is crucial for surgical treatment. Current routine noninvasive imaging techniques, including CT, MRI, and Ga-DOTA-somatostatin analog (DOTA-SSA) PET/CT, have limited sensitivity. Endoscopic ultrasound is highly...
8.
Mulders M, van Velthuysen M, Roes E, Hofland L, Sasano H, de Herder W, et al.
Eur J Endocrinol
. 2024 Jun;
191(1):K1-K4.
PMID: 38917055
Neuroendocrine tumors (NETs) are malignant neoplasms that can be associated with specific hormonal syndromes. We describe a novel syndrome of postmenopausal vaginal bleeding and ovarian estradiol overproduction due to ovarian...
9.
Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J, et al.
J Neuroendocrinol
. 2024 Jun;
36(8):e13420.
PMID: 38837825
[F]AlF-NOTA-octreotide ([F]AlF-OC) is a promising alternative for [Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging...
10.
Snaterse G, Taylor A, Moll J, ONeil D, Teubel W, van Weerden W, et al.
J Steroid Biochem Mol Biol
. 2023 Dec;
236:106446.
PMID: 38104728
Prostate cancer (PC) is dependent on androgen receptor (AR) activation by testosterone and 5α-dihydrotestosterone (DHT). Intratumoral androgen accumulation and activation despite systemic androgen deprivation therapy underlies the development of castration-resistant...